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Abstract 
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and 
diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the 
disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were 
available. 
Methods: Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated 
with first-generation antipsychotics (FGAs) were compared with an age and sex matched series of consecutive 
first-episode patients treated only with second-generation antipsychotics (SGAs). Rates of MetS were compared 
at baseline and after on average 3 years of treatment exposure.  
Results: At first episode there was no difference in the prevalence of MetS between the historic and the current 
cohort. Rates of MetS increased over time in both groups, but patients started on SGAs had a three times higher 
incidence rate of MetS (Odds Ratio 3.6, CI 1.7-7.5). The average increase in weight and body mass index was 
twice as high in patients started on SGA. The difference between the FGA and SGA group was no longer 
significant when patients started on clozapine and olanzapine were excluded.  
Conclusion: Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 
to 20 years ago. This finding counters the notion that the high rates of metabolic abnormalities in patients with 
schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Some 
SGAs have a significantly more negative impact on the incidence of MetS compared to FGAs in first-episode 
patients. 
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1. Introduction 
In the last decades prevalence rates of obesity have been rising globally (Kautiainen et al., 2002; Ogden et al., 
2006; Wang and Beydoun, 2007). This has contributed to increased rates of the metabolic syndrome (MetS) 
which will impact on physical health in the general population (Byrne and Wild, 2005; Ford et al., 2002, 2004). 
The metabolic syndrome is a risk factor for diabetes and cardiovascular disease (Byrne and Wild, 2005; 
Hennekens et al., 2005; Grundy, 2005; Isomaa et al., 2001; Yusuf et al., 2004). 
Several studies have shown high prevalence rates of MetS in patients with schizophrenia (Basu et al., 2004; 
Bobes et al., 2007; Cohn et al., 2004; Correll et al., 2006; De Hert et al., 2006a; Heiskanen et al., 2003; Holt et 
al., 2004; McEvoy et al., 2005; Meyer et al., 2005; Rejas et al., 2008; Sicras-Mainar et al., 2008; Srisurapanont et 
al., 2007; Thakore, 2005). Rates of MetS in people with schizophrenia are at least double compared to an age 
matched population sample (De Hert et al., 2006b). However, most studies were cross-sectional in nature. There 
are limited data on the evolution over time in patients with schizophrenia, in terms of cohort effects as well as 
within-person effects. 
Metabolic abnormalities have consistently been identified as a part of schizophrenic illness, even before the era 
of antipsychotic medication (Allison et al., 1999; Homel et al., 2002; Meduna et al., 1942; Raphael, 1921). The 
interest in this topic has been renewed since the introduction of second-generation antipsychotic s (SGAs) and 
their possible association with metabolic abnormalities (Allison and Casey, 2001; Henderson, 2005; Newcomer, 
2005, 2007a; Scheen and De Hert, 2005, 2007; Tschoner et al., 2007). Next to the impact on physical health 
these metabolic abnormalities are of major clinical concern, because of their association with a lower functional 
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outcome (Lyketsos et al., 2002), a worse perceived physical health (Dixon et al., 1999), poorer quality of life 
(Awad, 2004; De Hert et al., 2006c) and non-compliance (Weiden et al., 2004). 
The reasons that underlie the high prevalence of these metabolic abnormalities are much debated, especially 
when considering the possible role of SGAs in the occurrence of these abnormalities. Many studies have 
suggested a role of (certain) SGAs in the occurrence of metabolic abnormalities (Newcomer, 2005). Some 
studies have provided evidence for an increased prevalence of central obesity and glucose abnormalities such as 
impaired fasting glucose and insulin resistance in drug-naive first-episode patients, suggesting that metabolic  
disturbances may  even be  conceived as intermediary phenotypes associated with genetic risk for schizophrenia 
(de Leon and Diaz, 2007; Ryan et al., 2003; Spelman et al., 2007; Thakore et al., 2002; Thakore, 2005). Recently 
a few studies have explored the genetic variations associated with metabolic changes on antipsychotics (de Leon 
and Diaz, 2007; Ellingrod et al., 2008). Other authors have pointed to the increase in prevalence of metabolic 
abnormalities in the general population to explain the increase of metabolic abnormalities in schizophrenia (Holt 
et al., 2004; Holt and Pevelert, 2006). 
The current study aimed to compare two different cohorts of patients with schizophrenia admitted for their first 
episode of psychosis: a historic cohort consisting of subjects who were admitted between 1984 and 1995 and 
who were treated with first-generation antipsychotics (FGAs), and a current cohort of subjects with similar age 
and sex distribution who were admitted between 2000 and 2005 and who were treated with SGAs only. To 
evaluate the potential impact of population changes over time rates of MetS were compared between both groups 
at baseline before treatment was started. The differential impact of treatment with FGAs compared to SGAs, on 
the incidence and prevalence of MetS, was evaluated in a subsample of both cohorts on which prospective data 
over the course of treatment was available. Given the possible impact of SGAs on prevalence rates of metabolic 
abnormalities in schizophrenia, we hypothesized that rates of MetS would be similar for both cohorts at first 
admission, and that rates of MetS would increase over time in both groups, but significantly more for the current 
cohort as a result of treatment with SGAs. 
2. Methods 
Two cohorts of first-episode patients with schizophrenia were compared. Routinely, all patients got a physical 
examination and a fasting blood assessment when they were admitted to our university psychiatric hospital. 
Routine laboratory tests have been performed at our hospital in the same laboratory since the seventies. 
Assessment of triglycerides became available in 1981 and assessment of HDL cholesterol in 1984. 
The historic cohort is derived from a cohort of 1119 patients with schizophrenia consecutively admitted with 
schizophrenia between 1973 and 1992 (Peuskens et al., 1997; De Hert et al., 2001). All admitted first-episode 
patients between 1/1/1984 and 1/1/1995 with complete laboratory data at admission were selected for the study. 
All patients were treated with high-potency FGAs. 
The cohort of current first-episode patients came from an ongoing naturalistic follow-up. The baseline 
characteristics of included patients and study methods are described in detail elsewhere (De Hert et al., 2006a, 
b,c; van Winkel et al., 2006). All first-episode patients treated with SGAs with complete data were included. 
In both cohorts the follow-up data for the evaluation of MetS over the course of treatment were collected after at 
least 1 year of treatment exposure. The duration of treatment was matched between the two cohorts. 
The presence of the MetS was assessed using the adapted ATP-III criteria (Expert panel, 2001; Grundy et al., 
2005 (fasting glucose ≥ 100 mg/dl, plus including treatment for hypertension, - lipidemia and - glycemia as 
criteria, Tables 1 and 2)). In the historic cohort only weight and BMI were available because measuring waist 
circumference only became routine in recent years. Following Lean et al. (1995) a schizophrenia specific 
conversion from BMI to waist was calculated based on a regression analysis on data from 430 patients from the 
ongoing metabolic study (De Hert et al., 2006a). Waist circumference was predicted according to the following 
formula: waist = 33.0 + (2.4 × BMI) for men and waist = 27.9 + (2.4 × BMI) for women. 
Differences between cohorts on continuous variables were evaluated by means of one-way ANOVA. To evaluate 
the evolution over time of continuous variables as function of cohort, a cohort (2) × time ANOVA was 
performed. The associations between cohorts and categorical variables were assessed by chi-square tests. The 
occurrence of MetS in patients without MetS at baseline was predicted based on patient cohort through logistic 
regression. 
The study was approved by the ethical committee of our hospital (University Psychiatric Centre Catholic 
University Leuven) and all patients from the ongoing metabolic study gave written informed consent. 
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Table 1 : Demographics and data at baseline in both cohorts 
 Historic cohort 
(n = 148) 
Current cohort 
(n = 148) 
p** 
Age (years) 22.3 (±3.2) 22.1 (±3.1) ns 
Weight (kg) 67.6 (±11.9) 69.5 (±13.4) ns 
BMI (kg/m2) 22.3 (±3.4) 22.5 (±3.7) ns 
BP systolic (mmHg) 123 (±14) 118 (±14) ns 
BP diastolic (mmHg) 79 (±10) 72 (±11) ns 
Pulse (beats/min) 80 (±13) 80 (± 14) ns 
Glucose (mg/dl) 89 (±15) 84 (±7) 0.0055 
Cholesterol (mg/dl) 182 (±37) 172 (±35) ns 
Triglyceride (mg/dl) 100 (±56) 110 (±72) ns 
HDL (mg/dl) 53 (±16) 55 (±23) ns 
LDL (mg/dl) 103 (±35) 98 (±33) ns 
 
 n (%) n (%) p** 
ATP-III A at baseline* 8 (5.4%) 7 (4.7%) ns 
Waist (M>102cm, F>88cm) 15(10.1%) 13 (8.8%) ns 
BP (≥ 130/85 mm Hg) 65 (43.9%) 37 (25.0%) 0.0006 
HDL (M<40 mg/dl, F<50 mg/dl) 33 (22.3%) 33 (22.3%) ns 
TG (≥ 150 mg/dl) 17 (11.5%) 31 (20.9%) 0.0273 
Glucose (≥ 100 mg/dl) 14 (9.5%) 3 (2.0%) 0.0060 
*MetS if 3 of 5 criteria are met; **one-way ANOVA; ***Chi-square test. 
 
3. Results 
3.1. Patients and rate of MetS at baseline 
Between 1984 and 1995, 301 first-episode patients were admitted to our hospital. A complete laboratory 
assessment including all the parameters of Mets was available in 148 patients (49.2%) before start of medication. 
There were no significant differences between patients with or without a complete assessment, neither on clinical 
variables nor on available laboratory results. All patients were started on high-potency FGAs (butyrophenones, 
diphenylbutylperidines or thioxanthenes). 
The matched group of 148 patients treated only with SGAs was prospectively included at first episode between 
2000 and 2006. 
Both groups (n = 148) had similar age at first admission for the first episode (23.2 ± 3.4 versus 22.1 ± 3.2 years) 
and sex distribution (historic sample male 65.5%. versus the current sample male 71.6%). In both cohorts more 
than 95% were Caucasian and of native Belgian origin. 
The prevalence of MetS at first episode before start of treatment was similar in both groups (5.4%in FGA cohort 
and 4.7% in SGA cohort). Elevated blood-pressure and impaired fasting glucose were more frequent in the 
historic cohort while elevated triglycerides were more frequent in the current cohort. Apart from lower fasting 
glucose values in the current cohort, there were no significant differences between the groups on baseline 
metabolic parameters (Table 1). 
3.2. Rates of the metabolic syndrome over time 
Prospective data over the course of treatment were available in a subset of patients in both cohorts. In the historic 
group an assessment was available on 122 patients (82.4%), on average 3.7 years after the start of antipsychotic 
medication (± 1.4, min 1 and max 7.0 years). In the current cohort (n = 148), 108 patients (73.1%) had a 
complete assessment after a mean duration of treatment of 3.2 years (± 1.7, min 1 and max 6.9 years). The 
current cohort with complete assessments was younger at first admission (F = 7 .72, df 1,228 p = 0.0059) and 
had a shorter duration of follow-up compared to the historic group (F = 5.25, df 1,28 p = 0.0228). 
In patients with complete MetS assessments (baseline and after an average of 3 years exposure to antipsychotic 
medication) the rates of MetS were also comparable at baseline assessment, respectively 5.7% in the historic 
cohort (n = 122) and 5.6% in the current cohort (n = 108), although there were significant differences on 
individual MetS criteria (Table 2). At baseline there was no difference between the group in weight or BMI. 
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During treatment with FGAs (n = 122) there were 9.8% (n = 12) new incident cases of MetS resulting in a 
prevalence of 13.1%. In patients started on SGAs (n = 108) there was a more than 2 times higher incidence rate 
of 27.8% (n = 30) giving rise to a nearly 5-fold increase in prevalence of 30.6% compared to baseline (Table 2). 
The difference in rates after 3 years exposure on FGAs compared to SGAs was highly significant (Chi2 = 10.4, df 
1, p = 0.0013). 
In patients without MetS at baseline the risk of developing MetS was significantly greater in patients started on 
SGAs, Odds Ratio 3.6 (FGA as reference, CI 1.7-7.5). 
The difference over time was mainly explained by changes over time in glucose and triglycerides (Table 3). 
When patients in the SGA group treated with clozapine and olanzapine were excluded from the analysis the 
difference between the FGA and SGA groups was no longer significant (MetS rate at follow-up FGA 13.1% and 
SGA 16.1%, Chi2 = 0.308, df 1, p = 0.5790). 
 
Table 2 : -IIIA MetS over time with antipsychotic treatment 
 Baseline Incidence cases Follow-up* 
 n (%) n (%) n (%) 
Historic cohort on FGA  
(n = 122) 
7 (5.7%) 12 (9.8%) 16 (13.1%) 
Current cohort on SGA  
(n = 108) 
6 (5.6%) 30 (27.8%) 33 (31.6%) 
*A proportion of patients who met MetS criteria at baseline did not meet criteria at follow-up: 2.5% in the FGA group and 2.8% in the SGA 
group respectively 
 
Table 3 : valence of MetS and MetS criteria at baseline and at follow-up in all patients for whom follow-up data 
were available after on average 3 years 
 Historic cohort  
(n = 122) 
Current cohort 
(n = 108) 
p** 
 n (%) n (%)  
Baseline 
ATP-III A at baseline* 7 (5.7%) 6 (5.6%) ns 
Waist (M>102cm, F>88cm) 12 (9.8%) 12 (11.1%) ns 
BP(≥ 130/85 mm Hg) 52 (42.6%) 28 (25.9%) 0.0080 
HDL  (M<40 mg/dl, F<50 mg/dl) 28 (22.9%) 25 (23.1%) ns 
TG(≥ 150 mg/dl) 13 (10.7%) 25 (23.1%) 0.0109 
Glucose (≥ 100 mg/dl) 11 (9.0%) 3 (2.8%) (3) 0.0483 
 
Follow-up 
ATP-III A at follow-up* 16 (13.1%) 33 (30.6%) 0.0013 
Waist (M ≥ 94 cm, F ≥ 80 cm) 25 (20.5%) 33 (30.6%) ns 
BP(≥ 130/85 mm Hg)** 41 (33.6%) 45 (41.7%) ns 
HDL (M<40 mg/dl, F<50 mg/dl) 36 (29.5%) 41 (38.0%) ns 
TG(≥ 150 mg/dl) 35 (28.7%) 55 (50.9%) 0.0006 
Glucose (≥ 100 mg/dl) 8 (6.6%) 16 (14.8%) 0.0409 
*MetS if 3 of 5 criteria are met; **Chi-square test. 
 
3.3. Changes in individual metabolic parameters 
Significant weight changes over time occurred in both groups. Patients treated with FGAs gained 5.2 kg (± 9.1 
kg, min -12.0 kg, max 38.0 kg) on average, while people started on SGAs gained 11.5 kg ( ± 11.3 kg, min -12.2 
kg, max 56.7 kg). The difference in weight gain between the 2 cohorts was highly significant (F = 22.1, df 1,228 
p<0.0001), as well as the proportion of patients experiencing a >7% change in weight form baseline (FGA 
36.9% versus SGA 72.2%, Chi2 = 28.7, df 1, p<0.0001). 
The changes in weight resulted in significant changes in BMI over time and differences between the groups at 
follow-up (Table 3). In both groups there was a significant increase of overweight and obesity over time (FGA 
Chi2 = 54.2, df 1, p<0.0001; SGA Chi2 = 31.2, df 1, p<0.0001). The difference at follow-up between the 2 
cohorts was significant (Chi2 = 14.2, df 2, p=0.0008). 
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In both groups levels of HDL and triglycerides deteriorated significantly over time, the increase in triglycerides 
was significantly larger in patients on SGAs. For all laboratory metabolic parameters there was an effect of time 
and there were significant group × time interactions for glucose, total cholesterol and HDL cholesterol (Table 4). 
At 3 years follow-up impaired fasting glucose was more frequent in patients treated with SGAs (Chi = 4.2, df 1, 
p=0.0409). In both groups 2 patients developed diabetes. In the current cohort 2 patients were started on oral 
antidiabetic medication for sustained prediabetic abnormalities. 
There was no effect of age of first admission on any of the metabolic outcome measures. 
3.4. Effects of individual antipsychotic agents in the SGA cohort 
Of the patients started on SGAs 54.6% were still on the same antipsychotic at follow-up (mean duration of 
exposure 2.8 years ± 0.9). On average 2.6 ± 0.9 medication switches occurred during the 3 year follow-up. The 
mean duration of exposure to the SGAs the patients received at follow-up was 2.1 years (± 1.4). 
In the SGA group at 3 years follow-up the occurrence of MetS depends on which SGA the patients were on, 
MetS was significantly more prevalent in patients both treated with clozapine (58.3%) or olanzapine (47.1%) and 
least prevalent in patients on aripiprazole (10%) (Chi2 = 15.3, df 5, p=0.0092) (Table 5). 
 
Table 4 : Evolution of metabolic parameters over time in both cohorts in patients for whom follow-up data were 
available after on average 3 years 
 Historic cohort Current cohort p* 
 (n = 122)% (SD) (n = 108)% (SD)  
Duration follow-up 3.7 (±1.7) 3.2 (±1.4) 0.0228 
Age at baseline (years) 23.1 (±3.3) 21.9 (±3.2) 0.0059 
    
 BL FU BL FU Group FGA versus 
SGA 
Time Group by 
time 
Weight (kg) 67.0 (±12.0) 72.2 (±14.7) 69.8 (±13.8) 81.2 (±16.0) 0.0009 0.0001 0.0001 
BMI (kg/m2) 22.2 (±3.4) 23.9 (±4.3) 22.5 (±3.8) 26.3 (±4.7) 0.0060 0.0001 0.0001 
Glucose (mg/dl) 89 (±16) 88 (±17) 84 (±7) 89 (±10) ns 0.0071 0.0001 
Cholesterol 
(mg/dl) 
179 (±38) 185 (±42) 175 (±35.7) 194 (±43) ns 0.0001 0.0152 
Triglyceride 
(mg/dl) 
98 (±55) 126 (±70) 114 (±80) 158 (±92) 0.0038 0.0001 ns 
HDL (mg/dl) 53 (±16) 53 (±16) 56 (±25) 48 (±16) ns 0.0001 0.0008 
LDL (mg/dl) 100 (±38) 112 (±38) 100 (±35) 114 (±35) ns 0.0001 ns 
        
 BL FU BL FU 
BMI>25<30 14.7% 23.8% 15.7% 39.8% 
BMI>30 2.5% 9.0% 5.6% 17.6% 
*One-way ANOVA. 
 
Table 5 : ATP-IIIA MetS per antipsychotic in the SGA group 
 Baseline Follow-up 
 n (%) n (%) 
Amisulpride (n = 8) 1 (12.5%) 2 (25%) 
Aripiprazole (n = 10) 1 (10.0%) 1 (10.0%) 
Clozapine (n = 12) 1 (8.3%) 7 (58.3%) 
Olanzapine (n = 34) 1 (5.8%) 16 (47.1%) 
Risperidone (n = 24) 1 (4.1%) 4 (16.7%) 
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3.5. Long-term outcomes in the historic cohort 
During the follow-up of on average 3 years 15 patients of the historic cohort (5%) had died, 13 of which were 
suicides (4.3%) and 2 were cardiovascular deaths (0.7%), compared to no deaths in the current cohort. The 
difference in both suicide and mortality rate was significant (suicide Chi = 6.6, df 1, p=0.0063, mortality Chi2 = 
7.6, df 1, p=0.0036). 
On 130 patients of the historic cohort (43.2%) clinical and mortality data were available up to date (mean 
duration of follow-up 17.2 (± 2.7) years). Of this group 6, more patients had died (5 suicides and 1 cancer death) 
and another 8 patients had developed diabetes (6.1%). Two while still on a FGA and 6 when they were treated 
on SGA later in the course of the illness (4 on clozapine, of which 2 with ketoacidosis; 1 on olanzapine and 1 on 
risperidone). 
4. Discussion 
To our knowledge this is the first study evaluating baseline and prospective MetS data in first-episode patients 
comparing treatment with FGAs and SGAs. 
There were no significant difference in rates of MetS at the first episode between patients admitted to hospital 
today and patients admitted 15 to 20 years ago in the sample under study, although there were significant 
differences in rates on individual MetS criteria. This suggests that possible population lifestyle changes do not 
play an important role before treatment is started. 
At baseline patients in both groups had similar weight and BMI. Over an average duration of treatment of 3 
years there was a significant increase in weight and BMI in both groups. But the group started on SGAs 
experienced more significant weight gain, 11.8 kg on average. This dramatic weight gain in young people might 
well counterbalance the impact on compliance gained by inducing less extrapyramidal side-effects and will 
impact on quality of life (Awad, 2004; De Hert et al., 2006c; Weiden et al., 2004). 
The changes in weight were accompanied by increasing rates of MetS over the course of treatment. Rates 
doubled in patients started on FGAs but there was a 5 fold increase in patients started on SGAs. After 3 years of 
exposure of SGAs nearly 1 out of 3 first-episode patients met criteria of MetS. Most of the difference in rates of 
MetS between FGAs and SGAs was explained by weight gain and changes in triglycerides and fasting glucose 
levels. 
The odds of developing MetS in MetS naive patients were 3-fold in patients started on SGAs compared to FGAs, 
and there were significant differences between SGAs in their risk to induce MetS in first-episode patients. The 
differences observed between the FGA and SGA groups were mainly explained with the metabolically 
deleterious effects of clozapine and olanzapine. 
Our data on metabolic changes were in alignment with recent prospective studies in first-episode patents (Attux 
et al., 2007; Perez-Iglesias et al., 2008; Saddichha et al., 2007; Srisurapanont et al., 2007) and confirmed the 
differences between SGA in their liability to induce metabolic changes (Cohn and Sernyak, 2006; L'Italien et al., 
2007; Newcomer, 2005; van Winkel et al., 2008). 
MetS is a know risk factor for type-2 diabetes and cardiovascular disease (Byrne and Wild, 2005; Grundy 2005; 
Isomaa et al., 2001; Yusuf et al., 2004). The high rates of MetS in patients with schizophrenia and specifically 
patients treated with SGA should be a concern to  clinicians because  of the trend of still increasing premature 
mortality due to cardiovascular illness in people with schizophrenia while the risk for cardiovascular mortality in 
the general population continues to go down (Brown et al., 2000; Capasso et al., 2008; Hennekens et al., 2005, 
Joukamaa et al., 2001; Osby et al., 2000a,b; Osby, 2007). 
The long-term observation of patients from the historic cohort confirms the high rate of premature mortality, 
mainly due to suicide early in the course of the disorder. Although confirmation by other studies is needed the 
significant difference in suicide rates between first-episode patients treated with FGA and SGA is a clinically 
relevant finding that should be considered in the ongoing post CATIE debate on differences in clinical 
effectiveness of antipsychotics and metabolic side-effects. 
Limitations of the study are that the data were collected at only one site which might impact on generalisability 
of the results. We did not collect the exact drugs, switches over time between agents nor eventual polypharmacy 
in patients from the historic cohort. Although laboratory tests were performed in the same laboratory, techniques 
have changed over time, which may partly explain some of the differences found in individual laboratory results. 
Because we did not have waist measurements in the historic cohort we have used a conservative conversion 
factor. This factor was based on previous data obtained in a cross-sectional study in patients with schizophrenia 
(De Hert et al., 2006a). In both groups patients were prescribed medication but there was no way to control for 
actual compliance with medication. Both groups had a similar ethnic background and BMI at baseline but we 
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have no evaluation on family history of metabolic abnormalities nor measurements of fasting insulin in the 
historic cohort. Potential awareness and screening bias might have influenced the results because today patients 
are more closely monitored for potential metabolic side-effects. Lastly both age at first admission and length of 
follow-up significantly differed between groups with complete assessment both at baseline and follow-up. But 
the younger age and the shorter duration of follow-up in the current cohort would only potentially have favoured 
the SGA group. Given these possible sources of bias, the current results need to be interpreted with caution. 
Nevertheless, the results seem in line with existing literature suggesting a greater impact of SGAs on metabolic 
parameters, with the greatest impact for clozapine and olanzapine. 
To conclude, first-episode patients with schizophrenia are at high risk to develop MetS early in the course of the 
disorder.  The risk is significantly higher in patients started on SGAs. In line with published guidelines our 
results support the need for close monitoring of metabolic abnormalities and preferential use of metabolic neutral 
agents in this population as first line treatment option (Cohn and Sernyak, 2006; De Hert et al., 2006d; De Nayer 
et al., 2005; Marder et al., 2004; Newcomer, 2005, 2007a,b). 
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